Latest

Jul 17, 2026, 18:44 Arvind Krishna Rebuilt IBM Around Software. Now He Has to Make the AI Stack Outrun the Mainframe Cycle

Jul 17, 2026, 16:45 Nikhil Kamath Turned Market Access Into a Media Platform. Influence Now Needs Clearer Boundaries

Jul 17, 2026, 13:40 Lucy Guo Built Passes Around Creator Ownership. Trust Must Become the Subscription Advantage

Jul 17, 2026, 10:35 Shashank Kumar Is Rewiring Razorpay Around Payment Success. Reliability Has to Pay

Jul 16, 2026, 16:45 Ritesh Agarwal Has Taken PRISM Back to the IPO Gate. Investors Will Price the Quality of OYO's Profit

Jul 16, 2026, 15:37 Nikesh Arora Made Palo Alto Networks Cybersecurity’s Consolidator. Now He Has to Make the Stack Work as One

Jul 16, 2026, 13:40 Gukesh Dommaraju Became Chess's Youngest World Champion. Defending the Crown Is a Different Business

Jul 16, 2026, 10:35 Scott Wu Joined Devin With Windsurf. The Combined Product Must Earn a US$26 Billion Valuation

neuroscience

Huda Zoghbi, Director of the Jan and Dan Duncan Neurological Research Institute

Huda Zoghbi Opened a New Route to Rett Treatment. The Dose-Control Problem Will Decide Its Value

Huda Zoghbi’s latest Rett research attacks the disease’s narrow therapeutic window. Translating it will test whether precision neuroscience can deliver control, not simply a powerful one-time intervention.

Ardem Patapoutian, Professor and Presidential Endowed Chair in Neurobiology at Scripps Research

Ardem Patapoutian Found Pressure Sensors Across the Body. Drugmakers Must Decide Where Not to Intervene

Ardem Patapoutian’s PIEZO discoveries are expanding into common diseases with large Asian markets. Commercial value will depend on tissue-specific control, not the breadth of possible indications.